Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...

Eli Lilly and Company announced earlier this week ... Lilly markets tirzepatide as Zepbound for obesity and as Mounjaro for type II diabetes. Though demand for the two drugs remains massive ...

Copyright 2024 The Associated Press. All Rights Reserved. David Ricks, chair and CEO of Eli Lilly, fields a question during ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin and the rest of the state as it continues to grow. Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly's (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate ...

Eli Lilly and Novo Nordisk dominate the market ... Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.' ...